Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report)'s share price shot up 10.4% during mid-day trading on Wednesday . The stock traded as high as $2.45 and last traded at $2.44. 255,189 shares were traded during trading, an increase of 23% from the average session volume of 207,210 shares. The stock had previously closed at $2.21.
Analyst Ratings Changes
A number of research firms recently issued reports on GANX. Roth Capital upgraded shares of Gain Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Roth Mkm reiterated a "buy" rating and set a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, HC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $7.25.
View Our Latest Stock Analysis on Gain Therapeutics
Gain Therapeutics Trading Down 1.1 %
The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $69.22 million, a price-to-earnings ratio of -2.37 and a beta of 0.14. The firm's 50-day moving average is $2.03 and its 200 day moving average is $1.81.
Hedge Funds Weigh In On Gain Therapeutics
A number of hedge funds have recently modified their holdings of GANX. Geode Capital Management LLC increased its holdings in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company's stock valued at $484,000 after purchasing an additional 88,236 shares during the period. Renaissance Technologies LLC grew its position in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company's stock valued at $152,000 after buying an additional 72,000 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after buying an additional 44,750 shares during the period. Benedict Financial Advisors Inc. bought a new position in shares of Gain Therapeutics during the fourth quarter worth about $35,000. Finally, Sprott Inc. bought a new position in shares of Gain Therapeutics during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 11.97% of the company's stock.
About Gain Therapeutics
(
Get Free Report)
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Featured Articles
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
